UroNav Fusion Biopsy System
High Tech Prostate Imaging and Biopsy: Metro Chicago Surgical Oncology Now Offering MR/Ultrasound Fusion Biopsy
July 2015, Chicago, IL. – MCSO is proud to introduce a powerful new MR solution for analysis, planning and targeted biopsy of the prostate. This complete clinical MR solution for the prostate combines DynaCAD for Prostate with the UroNav fusion biopsy system - a combined solution which offers a truly new biopsy option for many patients with elevated and/or rising PSA levels.
Targeted MR/ultrasound biopsy is poised to become the new standard in prostate care, and MCSO is pleased to be one of the first urology groups in the area to offer this powerful solution to our patients. UroNav fuses pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time, for excellent delineation of the prostate and suspicious lesions.
After a patient has undergone a prostate MRI, our physicians utilize DynaCAD for Prostate to quickly visualize and evaluate suspicious lesions. Our UroNav fusion biopsy system uses this critical diagnostic information to provide our skilled urologists with a targeted approach to prostate biopsy.
The combination of DynaCAD for Prostate and UroNav, gives our urologists and radiologists the ability to offer their patients an alternative to remaining in an uncertain state of diagnosis after a prostate exam.
“We are confident that this new technology will bring new hope to patients and equip our healthcare providers with the latest technology to identify and target suspicious prostate lesions,” explains Dr. Allen Chernoff.
Other than skin cancer, prostate cancer has become the most common form of cancer in American men and the second-leading cause of cancer death in this population. As 1 man in 6 will be diagnosed with prostate cancer during his lifetime*, MCSO introduction of MR/ultrasound fusion biopsy could not have come at a more opportune time.
For more information about MCSO and MR/ultrasound fusion, please call us at (847) 673- 6505 or visit us on the web.